Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/11/2022 | $8.00 → $2.40 | Overweight → Equal Weight | Wells Fargo |
| 5/31/2022 | $7.00 | Outperform | Evercore ISI |
| 4/14/2022 | $8.00 | Overweight | Wells Fargo |
Wells Fargo downgraded Hyperfine from Overweight to Equal Weight and set a new price target of $2.40 from $8.00 previously
Evercore ISI initiated coverage of Hyperfine with a rating of Outperform and set a new price target of $7.00
Wells Fargo initiated coverage of Hyperfine with a rating of Overweight and set a new price target of $8.00
GUILFORD, Connecticut, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced third quarter 2024 financial results and provided a business update. "The Hyperfine team delivered yet another strong quarter of financial performance across revenue growth, gross margin expansion, and disciplined cash management while executing against several important priorities in our plans to expand into new sites of care and internationally," said Maria Sainz, Chief Executive Officer and President of Hy
Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the third quarter 2024 on Tuesday, November 12, 2024. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About th
─ Reports $3.6M in Q2 2024 Revenue; 50% Gross Margin─ Raises FY 2024 Revenue Guidance to $13-16M GUILFORD, Conn., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced second quarter 2024 financial results and provided a business update. "I am proud of the Hyperfine team, achieving record revenue and delivering meaningful progress across innovation and clinical initiatives in the quarter," said Maria Sainz, Chief Executive Officer and President of Hyperfine, Inc. "The opportunities ahead
SC 13G - Hyperfine, Inc. (0001833769) (Subject)
SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)
SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)
4 - Hyperfine, Inc. (0001833769) (Issuer)
4 - Hyperfine, Inc. (0001833769) (Issuer)
4 - Hyperfine, Inc. (0001833769) (Issuer)
Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced it has entered into a distribution agreement with Radiosurgery Global, Ltd. to develop the market in India. The distribution agreement also includes the countries of Malaysia, Indonesia, and Singapore through future expansion, offering Hyperfine, Inc. a significantly increased presence in Asia. The clinical value of the Swoop®
- Distributors appointed in France, the United Kingdom, and Italy - Industry veteran Enrico Barini joins as International Business Development Director Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced it has entered into agreements with three experienced and accomplished distributors to support commercial expansion plans of the Swoop® system into European markets with an initial focus on France, the United Kingdom, and Italy. In 2023, Hyperfine, Inc. obtained CE certification under the EU MDR and UKCA certificati
BUFFALO, N.Y., Nov. 29, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) ("22nd Century" or the "Company"), a biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced the appointment of Lawrence (Larry) Firestone as the Company's Chairman and Chief Executive Officer. Nora Sullivan, former Chair of the Board, commented, "Larry is a seasoned executive known for his 'hands-on' leadership style emphasizing teamwork, business alignment, continuous improvement, cost control and process optimization. His track record of success with fast growing public companies will serve 22nd Century well as it continues to execu
10-Q - Hyperfine, Inc. (0001833769) (Filer)
8-K - Hyperfine, Inc. (0001833769) (Filer)
10-Q - Hyperfine, Inc. (0001833769) (Filer)
The total number of Hyperfine AI-powered marketing authorizations places the company in a leading position on recently published FDA list.Hyperfine (NASDAQ:HYPR), the groundbreaking medical device company that has redefined brain imaging with the world's first FDA-cleared portable magnetic resonance brain imaging system—the Swoop® system—today announced the clearance of the ninth generation of AI-powered Swoop® system software. This advanced software significantly reduces scan times across multiple MR sequences without sacrificing image quality. The U.S. Food and Drug Administration (FDA) clearance of this software further solidifies Hyperfine as a leader in AI-powered health technology.Thes
The publication includes a subset of data from the ACTION PMR stroke study and provides early evidence that the Swoop® system is a promising tool for enabling critical stroke treatment choices in urgent care settings.
Portable ultra-low-field MR brain imaging provides affordable and accessible technology that may help physicians monitor ARIA and Alzheimer's disease progression in diverse professional care settings.Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that two presentations on the clinical utility of portable ultra-low-field MRI for Alzheimer's disease monitoring have been accepted in the developing topics poster sessions at the upcoming 2024 Alzheimer's Association International Conference, July 28–August 1 in Philadelphi
Intersocietal Accreditation Commission (IAC)'s release of new standards accepting ultra-low-field MRI technology enables accredited facilities to qualify for reimbursement from the US Centers for Medicare & Medicaid Services (CMS). Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the issuance of new MRI standards by the Intersocietal Accreditation Commission (IAC), a leading CMS-approved accrediting body. The new standards, effective immediately, now include portable MR scanning at the point of care. This press rele
The breadth of data being presented at the premier radiology meeting of 2024 illustrates the increasing relevance of portable, ultra-low-field MR brain imaging. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that ten scientific abstracts highlighting ultra-low-field imaging will be presented at the Radiological Society of North America (RSNA) 2024 Annual Meeting in Chicago. For Hyperfine, this marks the largest number of presentations at RSNA to date, underscoring the growing interest in and expanding applications
Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced plans to present at the upcoming BTIG Digital Health Forum on Monday, November 25, 2024. Management will also participate in the Mizuho Healthcare Conference in New York, NY, on Wednesday, December 11, 2024. To schedule a one-on-one meeting with management, please reach out to your BTIG representative, Mizuho representative, or the investor contact below. About the Swoop® Portable MR Imaging® System The Swoop® Portable MR Imaging® system is U.S. Food and Drug Admin